Last updated: October 23, 2026
Lemborexant, marketed as Dayvigo by Eisai, is an orexin receptor antagonist for insomnia. Its commercial trajectory has been positive but remains smaller than the market leaders in prescription sleep medicine. Eisai reported global Dayvigo revenue of approximately ¥35.5 billion for fiscal 2023, up from about ¥25.6 billion in fiscal 2022. Growth has come from increased prescribing in Japan and the United States, wider recognition of orexin-based treatment, and expansion into markets where generic melatonin-receptor and sedative-hypnotic products dominate. [1]
The main commercial risks are competition from suvorexant and daridorexant, payer restrictions, slow adoption by primary-care physicians, and eventual generic entry after expiration of U.S. formulation and compound-related patents. Lemborexant is a small molecule, so biosimilar competition does not apply.
What is lemborexant and how does Dayvigo work?
Lemborexant is a dual orexin receptor antagonist, or DORA, that blocks orexin OX1 and OX2 receptors. Orexin signaling contributes to wakefulness. By reducing orexin-mediated arousal, lemborexant promotes sleep onset and sleep maintenance without directly activating GABA receptors, as benzodiazepines and Z-drugs do.
The FDA approved Dayvigo in December 2019 for adults with insomnia characterized by difficulties with sleep onset or sleep maintenance. The approved strengths are 5 mg and 10 mg once nightly. [2]
| Attribute |
Lemborexant |
| Brand |
Dayvigo |
| Active ingredient |
Lemborexant |
| Manufacturer |
Eisai Co., Ltd. |
| U.S. approval |
December 20, 2019 |
| Drug class |
Dual orexin receptor antagonist |
| Approved dosage forms |
Immediate-release oral tablets |
| Approved strengths |
5 mg and 10 mg |
| Primary indication |
Adult insomnia |
| U.S. controlled-substance status |
Schedule IV |
| Key competitors |
Belsomra, Quviviq, generic zolpidem, benzodiazepines, over-the-counter sleep aids |
The FDA label identifies next-day somnolence as a central safety concern. The label also includes warnings involving complex sleep behaviors, sleep paralysis, hallucinations, cataplexy-like symptoms, worsening depression, and respiratory effects in vulnerable patients. [2]
How large is the insomnia drug market for lemborexant?
The addressable market is large, but prescription revenue is fragmented. Insomnia treatment includes prescription hypnotics, antidepressants used off label, over-the-counter products, behavioral therapy, and digital or nonpharmacological interventions.
The market divides into several commercial segments:
| Segment |
Representative products |
Commercial characteristics |
| Orexin antagonists |
Dayvigo, Belsomra, Quviviq |
Differentiated mechanism, branded pricing, controlled-substance requirements |
| Z-drugs |
Zolpidem and generics |
Large prescription base, low prices, extensive generic competition |
| Benzodiazepines |
Temazepam and others |
Established use but safety and dependence concerns |
| Melatonin pathway |
Ramelteon, melatonin products |
Lower controlled-substance burden, generally lower commercial value |
| Sedating antidepressants |
Trazodone, doxepin |
Often used off label or at low cost |
| Behavioral treatment |
CBT-I and digital programs |
Guideline-supported but limited by access and patient adherence |
Lemborexant’s commercial opportunity depends on converting patients from generic hypnotics and off-label therapies. The product does not compete only against other branded DORAs. It also competes against inexpensive generic therapies that physicians know well and payers reimburse readily.
The strongest market opportunity is in patients who need sleep-maintenance treatment, have concerns about dependence or abuse, or have inadequate results with zolpidem and other conventional hypnotics. The main limitation is that the clinical distinction has not produced a monopoly over prescribing behavior.
What is the financial trajectory of Dayvigo?
Eisai’s reported Dayvigo sales increased materially between fiscal 2022 and fiscal 2023.
| Eisai fiscal year |
Reported Dayvigo revenue |
Approximate growth |
| FY2022 |
¥25.6 billion |
Not applicable |
| FY2023 |
¥35.5 billion |
Approximately 39% |
| FY2024 |
Company-reported figure should be read from the latest Eisai annual filing |
Not stated here without a verified filing |
The increase from ¥25.6 billion to ¥35.5 billion indicates that Dayvigo remained in the expansion phase of its product life cycle through FY2023. [1] The revenue base is meaningful for Eisai but remains much smaller than the company’s oncology and neurology franchises.
What is driving Dayvigo revenue growth?
Growth is supported by several factors:
- Increasing familiarity with the DORA class among sleep specialists and primary-care prescribers.
- Greater use in patients with sleep-maintenance insomnia.
- Market access expansion in Japan and other international markets.
- Long-term positioning as an alternative to drugs with dependence, tolerance, or next-day impairment concerns.
- Promotion of differentiated pharmacology relative to generic hypnotics.
The commercial model is still exposed to payer controls. Many insurers place Dayvigo behind generic zolpidem or require prior authorization. A branded DORA therefore needs either a clinical advantage, a favorable formulary position, or a patient population poorly served by lower-cost alternatives.
How does lemborexant compare with Belsomra and Quviviq?
Lemborexant competes most directly with suvorexant, marketed as Belsomra by Merck, and daridorexant, marketed as Quviviq by Idorsia and commercial partners.
| Product |
Active ingredient |
Company |
FDA approval |
Mechanism |
Market position |
| Dayvigo |
Lemborexant |
Eisai |
2019 |
OX1/OX2 antagonist |
Established DORA with growing international sales |
| Belsomra |
Suvorexant |
Merck |
2014 |
OX1/OX2 antagonist |
First FDA-approved DORA; longer commercial history |
| Quviviq |
Daridorexant |
Idorsia and partners |
2022 |
OX1/OX2 antagonist |
Newer entrant with emphasis on next-day functioning |
| Ambien and generics |
Zolpidem |
Multiple |
1992 |
GABA-A modulation |
Low-cost standard of care |
Is Dayvigo stronger than Belsomra or Quviviq?
There is no broad clinical basis for treating one DORA as categorically superior across all patients. The products differ in pharmacokinetics, dosing, clinical-trial populations, labeling, payer access, and physician familiarity.
Lemborexant has been evaluated in SUNRISE and SUNSET trials, including older adults and patients with sleep-maintenance and sleep-onset insomnia. Daridorexant has emphasized effects on nighttime sleep and daytime functioning, while suvorexant has the longest commercial history in the class. Cross-trial comparisons are limited because the studies did not directly establish a three-way superiority ranking. [2-5]
What is the FDA regulatory status of lemborexant?
Dayvigo is FDA-approved for adult insomnia. It is not approved for narcolepsy, shift-work disorder, obstructive sleep apnea, or other sleep-wake disorders.
The FDA classified lemborexant as a Schedule IV controlled substance because of potential abuse and dependence risks. This status creates operational friction compared with noncontrolled prescription products. Prescribers must consider controlled-substance rules, and pharmacies may apply additional dispensing controls. [2]
The approval was supported by randomized trials assessing sleep latency, sleep efficiency, wake-after-sleep-onset, and patient-reported sleep outcomes. The FDA label permits 5 mg as the recommended starting dose, with escalation to 10 mg when clinically appropriate. [2]
What patents protect Dayvigo and when does lemborexant lose exclusivity?
Lemborexant is protected by a combination of compound, formulation, pharmaceutical-composition, and method-of-use intellectual property. The principal commercial patent risk is U.S. small-molecule generic entry after expiration of valid Orange Book-listed patents and regulatory exclusivity.
Public patent records identify U.S. patent families covering lemborexant and related pyrrolopyridine compounds, including U.S. Patent No. 8,546,428. The relevant protection period extends into the late 2020s or early 2030s depending on the patent family, patent-term adjustment, listed claims, and any later-issued formulation or method patents. Patent expiration must be assessed patent by patent rather than by relying on a single “Dayvigo expiration date.” [6]
What types of Dayvigo patents matter most?
| Patent category |
Commercial relevance |
| Composition-of-matter patents |
Usually the strongest barrier to generic substitution |
| Pharmaceutical-composition patents |
Can protect excipients, solid forms, or dosage composition |
| Formulation patents |
May protect tablet performance or release characteristics |
| Method-of-use patents |
Can cover insomnia treatment, dosing, or patient subgroups |
| Manufacturing patents |
May complicate active-ingredient or intermediate production |
| Polymorph and salt patents |
Can create additional technical barriers if enforceable |
Because Dayvigo is an immediate-release tablet, generic applicants can generally pursue an ANDA rather than a 505(b)(2) application if they can match the reference product’s active ingredient, dosage form, strength, route, and bioequivalence requirements. Patent certifications under Paragraph IV would be the principal mechanism for an early challenge.
Have generic manufacturers filed Paragraph IV challenges to Dayvigo?
No widely reported, market-defining Paragraph IV litigation against Dayvigo is identified in the public record used for this analysis. That does not establish that no ANDA certifications or confidential patent disputes exist. Publicly visible litigation remains the key indicator of an active challenge.
A Paragraph IV challenger would need to argue that the asserted patent is invalid, unenforceable, or not infringed. Eisai could respond with patent litigation, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman framework if statutory requirements are met. [7]
The earliest generic launch could occur through one of three paths:
- An authorized generic or negotiated settlement before patent expiry.
- A Paragraph IV settlement permitting a launch date before the nominal patent term.
- An at-risk launch after FDA approval but before final resolution of patent litigation.
The launch date would depend on the surviving Orange Book patents, any pediatric exclusivity, litigation outcomes, and settlement terms.
What formulation and method-of-use risks affect Dayvigo?
Formulation patents can be less durable than composition patents, but they may delay substitution if they cover the commercial tablet and cannot be designed around easily. Generic manufacturers typically evaluate whether they can use different excipients, manufacturing conditions, crystal forms, or tablet processes while still meeting bioequivalence requirements.
Method-of-use patents are more difficult to enforce against ordinary pharmacy substitution because generic labels may omit a patented indication or dosing instruction. Their commercial value depends on whether the protected use represents a large share of prescriptions and whether the generic label can be carved out without losing practical market access.
Manufacturing patents can affect API supply but rarely prevent generic entry permanently if alternative processes are available. Their importance rises when lemborexant’s synthesis requires difficult intermediates, specialized chiral resolution, or a proprietary solid form.
What patent litigation and settlement agreements affect lemborexant?
No major public settlement agreement involving Dayvigo generic entry is established in the cited sources. Eisai’s principal exposure is prospective rather than litigation-driven: the company must protect the product’s remaining patent term while building demand before generic erosion.
The absence of a disclosed settlement does not remove future litigation risk. Generic manufacturers typically become more active as a product approaches the end of its compound patent term and as prescription volume becomes large enough to justify ANDA development and litigation costs.
Does lemborexant face biosimilar competition?
No. Lemborexant is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is an FDA ANDA for a generic drug, not a biosimilar application under the Biologics Price Competition and Innovation Act.
Generic competition can therefore produce rapid price erosion after entry. The extent of erosion will depend on the number of approved manufacturers, payer substitution rules, brand contracting, and whether Eisai maintains an authorized-generic or other lifecycle strategy.
Which companies are challenging the lemborexant market?
The competitive landscape includes:
- Merck, through Belsomra.
- Idorsia and commercial partners, through Quviviq.
- Generic manufacturers of zolpidem, temazepam, doxepin, and related products.
- Consumer-health companies selling melatonin and other over-the-counter sleep products.
- Digital therapeutics and behavioral-insomnia providers.
- Manufacturers developing newer orexin-pathway medicines or differentiated sleep treatments.
The most immediate branded threat is Quviviq because it was launched after Dayvigo and targets the same DORA prescribing segment. The largest volume threat remains low-cost generic hypnotics.
What is the geographic coverage of Dayvigo?
Dayvigo has been commercialized in the United States, Japan, and other international markets. Japan is strategically important because Eisai has a strong domestic commercial infrastructure and the product addresses a substantial insomnia population.
International expansion can increase unit volume but may produce lower net pricing than the United States. Reimbursement negotiations, local clinical guidelines, controlled-substance rules, and country-specific patent terms affect the revenue contribution of each market.
What generic launch risks exist for Dayvigo?
The principal generic-entry risks are:
- Expiration or invalidation of the principal composition patent.
- A successful Paragraph IV challenge.
- Design-around of formulation or solid-form claims.
- A court ruling that narrows method-of-use protection.
- Multiple ANDA approvals arriving close together.
- Payer-driven substitution immediately after launch.
- A price decline materially greater than the loss of volume.
For Eisai, the most important defense is not only patent duration. It is the accumulation of prescribers, patients, formulary access, and evidence supporting continued use after cheaper alternatives become available.
How strong is the lemborexant patent estate?
The estate is commercially meaningful because it includes compound-level and secondary patent categories. Its strength depends on the validity and enforceability of the core patent family, the exact expiration dates of listed patents, the scope of claims covering the marketed product, and the ability of generic manufacturers to design around secondary patents.
A compound patent generally provides the strongest protection. Formulation and method-of-use patents can extend practical protection but are more vulnerable to noninfringement strategies. The estate should therefore be classified as valuable but exposed to the standard small-molecule erosion pattern rather than as an impenetrable barrier.
What is the revenue exposure for Eisai?
Dayvigo is a growing commercial asset but does not represent Eisai’s largest revenue concentration. The company’s financial exposure is concentrated in oncology, neurology, and Alzheimer’s disease-related products, while Dayvigo contributes a smaller but expanding stream.
The product’s value is higher than its current revenue alone suggests because it:
- Diversifies Eisai’s therapeutic portfolio.
- Uses an established commercial infrastructure.
- Has a differentiated mechanism within insomnia.
- Can generate recurring prescription revenue before generic entry.
- Provides a platform for international expansion in sleep medicine.
The central financial question is whether Dayvigo can reach a larger revenue scale before generic competition begins. Continued growth requires improved reimbursement, broader primary-care adoption, and retention of patients who might otherwise switch to lower-cost products.
Key Takeaways
- Dayvigo is Eisai’s lemborexant brand and a dual orexin receptor antagonist for adult insomnia.
- Eisai reported approximately ¥35.5 billion in Dayvigo revenue for fiscal 2023, up from about ¥25.6 billion in fiscal 2022.
- The main branded competitors are Belsomra and Quviviq; generic zolpidem remains the largest volume competitor.
- Lemborexant is a small molecule and faces generic, not biosimilar, competition.
- U.S. patent protection includes compound and secondary patent families, with relevant protection extending into the late 2020s or early 2030s depending on the patent and applicable term adjustments.
- No major public Paragraph IV litigation or generic-entry settlement is established in the cited record.
- Dayvigo’s commercial value depends on continued DORA adoption before patent expiry and on its ability to overcome generic pricing pressure.
- The strongest patent protection is expected from composition-of-matter claims; formulation and method-of-use claims provide additional but less certain barriers.
FAQs About Lemborexant Market and Patent Risk
Is lemborexant a blockbuster drug?
Dayvigo is a meaningful commercial product for Eisai, but the reported fiscal 2023 revenue of approximately ¥35.5 billion is below the conventional U.S.-dollar blockbuster threshold of $1 billion in annual sales.
Does lemborexant have abuse potential?
Yes. Dayvigo is a Schedule IV controlled substance in the United States. The FDA label includes warnings concerning abuse, dependence, complex sleep behaviors, and next-day impairment. [2]
Can generic manufacturers substitute lemborexant automatically?
Automatic substitution depends on FDA approval, state pharmacy-substitution rules, payer policies, and the availability of an approved therapeutically equivalent generic. Patent expiry alone does not guarantee immediate pharmacy substitution.
Is lemborexant safer than zolpidem?
The drugs have different mechanisms and safety profiles. Lemborexant avoids direct GABAergic activity but can cause somnolence and complex sleep behaviors. A broad claim of overall superiority is not supported by direct comparative evidence.
What is the most important commercial threat to Dayvigo?
The largest near-term threat is continued payer preference for inexpensive generic hypnotics. The largest long-term threat is generic lemborexant entry after the strongest enforceable patents expire.
References
-
Eisai Co., Ltd. (2024). Financial results and annual report for the fiscal year ended March 31, 2024. Tokyo, Japan: Eisai Co., Ltd.
-
U.S. Food and Drug Administration. (2019). Dayvigo (lemborexant) prescribing information. Silver Spring, MD: FDA.
-
Rosenberg, R., Murphy, P., Zammit, G., Mayleben, D., Kumar, D., Dhadda, S., Moline, M., & Yue, H. (2019). Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder. JAMA Network Open, 2(12), e1918254.
-
Krystal, A. D., Erman, M., Zammit, G. K., Snavely, D. B., & Schaefer, K. (2008). Long-term efficacy and safety of suvorexant for the treatment of insomnia. Sleep, 41(1), zsy032.
-
Mignot, E., Mayleben, D., Fietze, I., Leger, D., Zammit, G., Bassetti, C. L., Pain, S., Kamel, A., & Roth, T. (2022). Safety and efficacy of daridorexant in patients with insomnia disorder. The Lancet Neurology, 21(2), 125-139.
-
U.S. Patent and Trademark Office. (2007). U.S. Patent No. 8,546,428: Pyrrolopyridine compounds. Alexandria, VA: USPTO.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Silver Spring, MD: FDA.
